The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction
Authors
Keywords
-
Journal
Annals of the New York Academy of Sciences
Volume 1263, Issue 1, Pages 29-40
Publisher
Wiley
Online
2012-07-26
DOI
10.1111/j.1749-6632.2012.06674.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.
- (2017) D. H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.
- (2017) J. Blay et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men
- (2013) Patrick Haentjens ANNALS OF INTERNAL MEDICINE
- Increased fracture rate in women with breast cancer: a review of the hidden risk
- (2011) Jean-Jacques Body BMC CANCER
- Denosumab decreases cortical porosity in postmenopausal women with low BMD
- (2011) S.K. Boyd et al. BONE
- Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody
- (2011) Paul J. Kostenuik et al. BONE
- Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys
- (2011) Michael S. Ominsky et al. BONE
- Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
- (2011) W. C. Dougall CLINICAL CANCER RESEARCH
- Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
- (2011) B. J. Edwards et al. CLINICAL CANCER RESEARCH
- Fracture risk in men with prostate cancer: A population-based study
- (2011) L Joseph Melton et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
- (2011) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
- (2011) Matthew Austin et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
- (2011) Socrates Papapoulos et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- (2011) Eitan Amir et al. JNCI-Journal of the National Cancer Institute
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling
- (2011) Wei Tan et al. NATURE
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
- (2011) N. B. Watts et al. OSTEOPOROSIS INTERNATIONAL
- Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
- (2010) Jude Canon et al. BONE
- Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
- (2010) Pamela M. Holland et al. CANCER BIOLOGY & THERAPY
- Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
- (2010) Ego Seeman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study
- (2010) Roger MD Zebaze et al. LANCET
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
- (2010) David Thomas et al. LANCET ONCOLOGY
- RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
- (2010) Eva Gonzalez-Suarez et al. NATURE
- Control of mammary stem cell function by steroid hormone signalling
- (2010) Marie-Liesse Asselin-Labat et al. NATURE
- Progesterone induces adult mammary stem cell expansion
- (2010) Purna A. Joshi et al. NATURE
- Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
- (2010) Daniel Schramek et al. NATURE
- Do RANKL inhibitors (denosumab) affect inflammation and immunity?
- (2010) S. Ferrari-Lacraz et al. OSTEOPOROSIS INTERNATIONAL
- Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland
- (2010) M. Beleut et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe
- (2009) Ethel S. Siris et al. AMERICAN JOURNAL OF MEDICINE
- Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin
- (2009) Xiaodong Li et al. BONE
- Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats
- (2009) Verena Proell et al. BONE
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
- (2009) Dana Bliuc JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
- (2009) Shabbir M.H. Alibhai et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
- (2009) Karim Fizazi et al. JOURNAL OF UROLOGY
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice
- (2008) S. A. J. Lloyd et al. CALCIFIED TISSUE INTERNATIONAL
- Osteotropic cancers: From primary tumor to bone
- (2008) Jeroen T. Buijs et al. CANCER LETTERS
- Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
- (2008) Ann E. Kearns et al. ENDOCRINE REVIEWS
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*
- (2008) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
- (2008) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
- (2008) Georgiana K. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- RANK ligand as a therapeutic target for bone metastases and multiple myeloma
- (2007) G. David Roodman et al. CANCER TREATMENT REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started